From the point of view of the proficiency of DNA damage repair, BRCA1-associated TNBCs are not a homogenous group; therefore, they should not be regarded as such when patients with this type of cancer are enrolled in clinical trials of neoadjuvant chemotherapy with cisplatin or PARP inhibitors. This evidence concerns the gene BRCA1 and cancer.